Astellas Entered Into Definitive Agreement to Acquire Iveric Bio for $40/Share In Cash
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P.
Deutsche Bank Agreed To Acquire Numis For 350 Pence/Share
The Board of Numis and the Management Board of Deutsche Bank are pleased to announce that they have reached agreement on the terms of a recommended all-cash offer by Deutsche Bank for the entire issued and to be issued share capital of Numis. It is intended that the Transaction will be implemented by way of a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006.
Clearside Biomedical Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
Clearside Biomedical, Inc. (Nasdaq: CLSD) announced today that several key poster presentations were delivered on the Company's suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting.
Mesoblast Completed A Global Private Placement Raising Approximately US$40M
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share.
Adverum Biotechnologies Presented Nonclinical Data Sunday at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced nonclinical data supporting the two doses of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) being evaluated in the Phase 2 LUNA trial and the potential for staggered, bilateral administration in the treatment of wet AMD.
IDEAYA Announces Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma; Confirmed Overall Response Rate Of 45%,…
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma (MUM) patients (ClinicalTrials.gov Identifier: NCT03947385).
Bed Bath & Beyond Announced Early Sunday It Filed Voluntary Chapter 11 Petitions
Bed Bath & Beyond Inc. (NASDAQ: BBBY) today announced that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief under Chapter 11 of the U.S.
Shift4 Payments Issued Response to Blue Orca Short Report Published Wednesday; CEO Jared Isaacman Said “I only purchased shares in 2022 and never sold stock on the market as it was implied.”
Dear Fellow Shareholders,
As some of you may have seen, we were the subject of a short seller's report yesterday. Having founded this
business when I was 16 and spending the last 24 years in constant pursuit of improvement, I am no stranger
to critics. We knew long before our first day at the New York Stock Exchange that operating a public
company attracts critics, both fairly and unfairly.
Goldman Sachs Expands Visual Structuring Capabilities Into Equities, Crypto And Precious Metals
Today, Goldman Sachs announced the expansion of Visual StructuringTM into equities, crypto and precious metals, as well as the launch of web and Android versions in addition to the original iOS mobile application for FX launched in September 2022.